论文部分内容阅读
目的分析52例耐多药结核病人个体化治疗的疗效。方法将耐药病人分成两组,一般耐药(I组)和耐多药组(Ⅱ组)制定个体化方案。观察痰菌阴转率和X射线好转率。结果两组病例治疗6、12及24个月,痰菌阴转率及X射线好转率分别:I组:70%,50%;90%,90%;90%,90%。Ⅱ组:62.5%,43.75%;87.5%,75%;81.3%,81.3%。两组疗效对比有显著性差异(P<0.05)。结论个体化方案治疗失败与耐多种药物,肺部不可逆性病是广泛有关,根据药敏结果及建立个体化的合理有效的化疗方案,对MDR-TB十分重要。
Objective To analyze the curative effect of individualized treatment of 52 MDR-TB patients. Methods The resistant patients were divided into two groups, general resistance (group I) and multidrug-resistant group (group II) to develop individualized regimens. Observe sputum negative conversion rate and X-ray conversion rate. Results The two groups of patients treated for 6, 12 and 24 months, the sputum negative conversion rate and X-ray improvement rates were: I group: 70%, 50%; 90%, 90%; 90%, 90%. Group Ⅱ: 62.5%, 43.75%; 87.5%, 75%; 81.3%, 81.3%. There was significant difference between the two groups (P <0.05). Conclusion Individualized regimens failed to respond to various drugs and pulmonary irreversible diseases. According to the drug susceptibility results and the establishment of a rational and effective chemotherapy regimen, it is very important for MDR-TB.